FY2025 EPS Forecast for Fate Therapeutics Raised by Analyst

Fate Therapeutics, Inc. (NASDAQ:FATE) – Stock analysts at Cantor Fitzgerald upped their FY2025 earnings estimates for Fate Therapeutics in a research note issued on Tuesday, March 18th. Cantor Fitzgerald analyst L. Watsek now expects that the biopharmaceutical company will post earnings per share of ($1.20) for the year, up from their prior forecast of ($1.67). The consensus estimate for Fate Therapeutics’ current full-year earnings is ($1.63) per share.

A number of other research analysts have also weighed in on FATE. Needham & Company LLC reaffirmed a “hold” rating on shares of Fate Therapeutics in a research note on Thursday, March 6th. StockNews.com cut Fate Therapeutics from a “hold” rating to a “sell” rating in a report on Tuesday, March 11th. Wedbush reissued a “neutral” rating and issued a $5.00 price target on shares of Fate Therapeutics in a research note on Thursday, March 6th. Wells Fargo & Company reduced their price objective on Fate Therapeutics from $5.00 to $4.00 and set an “equal weight” rating for the company in a research report on Thursday, March 6th. Finally, Stifel Nicolaus dropped their target price on Fate Therapeutics from $5.00 to $3.00 and set a “hold” rating on the stock in a research report on Thursday, March 6th. One equities research analyst has rated the stock with a sell rating, seven have issued a hold rating and two have given a buy rating to the stock. According to data from MarketBeat, the stock currently has an average rating of “Hold” and an average target price of $5.50.

Fate Therapeutics Stock Performance

Shares of FATE opened at $0.91 on Thursday. The stock has a 50 day simple moving average of $1.21 and a 200 day simple moving average of $2.18. Fate Therapeutics has a 52-week low of $0.87 and a 52-week high of $7.65. The firm has a market capitalization of $104.73 million, a PE ratio of -0.55 and a beta of 2.26.

Fate Therapeutics (NASDAQ:FATE) last posted its earnings results on Wednesday, March 5th. The biopharmaceutical company reported ($0.31) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.44) by $0.13. The firm had revenue of $1.86 million during the quarter, compared to analysts’ expectations of $1.57 million. Fate Therapeutics had a negative return on equity of 45.88% and a negative net margin of 1,325.43%.

Institutional Inflows and Outflows

Several institutional investors have recently made changes to their positions in the stock. Thrivent Financial for Lutherans grew its stake in shares of Fate Therapeutics by 24.7% in the third quarter. Thrivent Financial for Lutherans now owns 125,370 shares of the biopharmaceutical company’s stock valued at $439,000 after buying an additional 24,804 shares in the last quarter. Intech Investment Management LLC bought a new position in shares of Fate Therapeutics in the 3rd quarter valued at about $108,000. FMR LLC increased its stake in shares of Fate Therapeutics by 25.9% during the 3rd quarter. FMR LLC now owns 227,981 shares of the biopharmaceutical company’s stock worth $798,000 after purchasing an additional 46,892 shares during the last quarter. BNP Paribas Financial Markets increased its stake in shares of Fate Therapeutics by 1,307.6% during the 3rd quarter. BNP Paribas Financial Markets now owns 174,148 shares of the biopharmaceutical company’s stock worth $610,000 after purchasing an additional 161,776 shares during the last quarter. Finally, Walleye Capital LLC raised its holdings in shares of Fate Therapeutics by 263.5% in the 3rd quarter. Walleye Capital LLC now owns 67,609 shares of the biopharmaceutical company’s stock valued at $237,000 after purchasing an additional 49,009 shares during the period. Institutional investors and hedge funds own 97.54% of the company’s stock.

Fate Therapeutics Company Profile

Fate Therapeutics, Inc, a clinical-stage biopharmaceutical company, develops programmed cellular immunotherapies for cancer and immune disorders worldwide. The company's chimeric antigen receptor (CAR)-targeted NK and T-cell product candidates include FT576 to treat multiple myeloma, and FT522, to treat lymphoma and autoimmune disorders.